We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-3.83%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$708M
AUM Growth
-$202M
Cap. Flow
-$159M
Cap. Flow %
-22.52%
Top 10 Hldgs %
51.4%
Holding
107
New
17
Increased
18
Reduced
23
Closed
41

Top Buys

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$24.4M
2
JNJ icon
Johnson & Johnson
JNJ
+$23.8M
3
PFE icon
Pfizer
PFE
+$14.9M
4
AMD icon
Advanced Micro Devices
AMD
+$11.9M
5
ZIM icon
ZIM Integrated Shipping Services
ZIM
+$10.2M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$39.7M
2
LLY icon
Eli Lilly
LLY
+$23M
3
MSFT icon
Microsoft
MSFT
+$17M
4
AMZN icon
Amazon
AMZN
+$14M
5
META icon
Meta Platforms (Facebook)
META
+$14M

Sector Composition

Rank Sector Weight
1 Healthcare 72.32%
2 Industrials 4.31%
3 Technology 3.78%
4 Financials 1.4%
5 Communication Services 1.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AZN icon
1
AstraZeneca
AZN
$263B
$55.5M 7.85%
418,409
-109,325
-21% -$13.1M
JNJ icon
2
Johnson & Johnson
JNJ
$618B
$52.3M 7.39%
295,023
+139,900
+90% +$23.8M
SNY icon
3
Sanofi
SNY
$103B
$49.9M 7.06%
972,415
-110,985
-10% -$5.73M
QQQ icon
4
PUT
Invesco QQQ Trust
QQQ
$453B
$45.7M 6.46%
+126,000
New +$44.7M
ABBV icon
5
AbbVie
ABBV
$443B
$31M 4.38%
190,994
-273,200
-59% -$39.7M
FIVN icon
6
CALL
FIVE9
FIVN
$2.11B
$27.5M 3.88%
248,900
+70,400
+39% +$8.19M
PFE icon
7
Pfizer
PFE
$143B
$26.7M 3.77%
515,070
+286,542
+125% +$14.9M
NVO
8
Novo Nordisk
NVO
$208B
$26.4M 3.73%
+474,800
New +$24.4M
SWTX
9
DELISTED
SpringWorks Therapeutics
SWTX
$26M 3.67%
460,025
+117,459
+34% +$6.72M
MRK icon
10
Merck
MRK
$322B
$22.8M 3.23%
278,200
-68,223
-20% -$5.38M
SNDX icon
11
Syndax Pharmaceuticals
SNDX
$1.69B
$22.2M 3.14%
1,277,413
+100,828
+9% +$1.7M
LLY icon
12
Eli Lilly
LLY
$1.02T
$20.1M 2.85%
70,295
-89,400
-56% -$23M
TEVA icon
13
CALL
Teva Pharmaceuticals
TEVA
$40.8B
$17.7M 2.51%
+1,890,000
New +$15.8M
BMRN icon
14
BioMarin Pharmaceuticals
BMRN
$11.6B
$16.3M 2.3%
211,326
-5,651
-3% -$473K
KYMR icon
15
Kymera Therapeutics
KYMR
$8.51B
$15.6M 2.2%
368,061
+49,394
+16% +$2.09M
ISEE
16
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$13M 1.84%
774,130
+289,129
+60% +$4.27M
GNRC icon
17
Generac Holdings
GNRC
$11.6B
$12.5M 1.77%
42,211
+154
+0.4% +$46.2K
CRNX icon
18
Crinetics Pharmaceuticals
CRNX
$8.84B
$11.5M 1.62%
521,947
+98,699
+23% +$2M
AMD icon
19
Advanced Micro Devices
AMD
$776B
$10.9M 1.55%
+100,000
New +$11.9M
MRUS
20
DELISTED
Merus
MRUS
$10.8M 1.53%
409,141
+68,190
+20% +$1.83M
ZIM icon
21
ZIM Integrated Shipping Services
ZIM
$3.04B
$10.8M 1.52%
+148,000
New +$10.2M
KURA icon
22
Kura Oncology
KURA
$800M
$9.94M 1.41%
618,244
-213,994
-26% -$3.09M
CCCC icon
23
C4 Therapeutics
CCCC
$385M
$8.79M 1.24%
362,528
-35,941
-9% -$873K
KDNY
24
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$8.08M 1.14%
493,677
+382,024
+342% +$5.19M
ALT icon
25
Altimmune
ALT
$552M
$7.96M 1.12%
1,306,953
+62,712
+5% +$462K
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2022 Portfolio in Review

As of Q1 2022, Sphera Funds Management held 107 positions worth $708M, down 22% from $910M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Sphera Funds Management withdrew a net $159M in Q1 2022, closing 41 positions and reducing 23 holdings. Its most notable exit was Microsoft, an estimated $17M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 69% a quarter earlier, followed by Industrials and Technology.

Against the trend, Sphera Funds Management opened a new position in Novo Nordisk worth $26.4M.

  • Sphera Funds Management's largest Q1 2022 buy was Novo Nordisk: 474,800 shares worth $26.4M.
  • Sphera Funds Management added most to Johnson & Johnson in Q1 2022, an estimated $23.8M increase.
  • Sphera Funds Management's biggest Q1 2022 reduction was AbbVie, cutting an estimated $39.7M.
  • Sphera Funds Management fully exited Microsoft in Q1 2022, selling an estimated $17M.
  • Sphera Funds Management's ten largest holdings make up 51% of its $708M portfolio in Q1 2022.
  • Sphera Funds Management opened 17 new positions and closed 41 in Q1 2022.
  • Sphera Funds Management's portfolio value fell 22% quarter-over-quarter to $708M.

Based on Sphera Funds Management's 13F filing for Q1 2022, filed 16 May 2022.